Comparison of the central and renal dopamine-1 receptor. 1990

A Sidhu, and R A Felder, and P A Jose, and P H Fishman
Department of Pediatrics, Georgetown University, Washington, D.C.

The dopamine D-1 receptor from striatal membranes was compared with the dopamine DA-1 receptor from renal proximal tubules. The dopamine-1 receptors were solubilized with 1% sodium cholate and phospholipids after pretreatment with the dopamine-1 agonist, SKF R-38393. The soluble receptors were reconstituted into phospholipid vesicles after removal of sodium cholate. The receptors were studied by radioligand binding using the dopamine-1 antagonist [125I]-SCH 23982. The reconstituted dopamine D-1 and DA-1 receptor densities were similar. However, the affinity of the solubilized D-1 receptor was 17-fold greater than the solubilized DA-1 receptor. The affinity of membrane bound D-1 receptor to the radioligand was also greater than that noted for membrane bound DA-1 receptor. The mechanism for this difference remains to be determined.

UI MeSH Term Description Entries
D007687 Kidney Tubules, Proximal The renal tubule portion that extends from the BOWMAN CAPSULE in the KIDNEY CORTEX into the KIDNEY MEDULLA. The proximal tubule consists of a convoluted proximal segment in the cortex, and a distal straight segment descending into the medulla where it forms the U-shaped LOOP OF HENLE. Proximal Kidney Tubule,Proximal Renal Tubule,Kidney Tubule, Proximal,Proximal Kidney Tubules,Proximal Renal Tubules,Renal Tubule, Proximal,Renal Tubules, Proximal,Tubule, Proximal Kidney,Tubule, Proximal Renal,Tubules, Proximal Kidney,Tubules, Proximal Renal
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D000345 Affinity Labels Analogs of those substrates or compounds which bind naturally at the active sites of proteins, enzymes, antibodies, steroids, or physiological receptors. These analogs form a stable covalent bond at the binding site, thereby acting as inhibitors of the proteins or steroids. Affinity Labeling Reagents,Labeling Reagents, Affinity,Labels, Affinity,Reagents, Affinity Labeling
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001552 Benzazepines Compounds with BENZENE fused to AZEPINES.
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D015259 Dopamine Agents Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. Dopamine Drugs,Dopamine Effect,Dopamine Effects,Dopaminergic Agents,Dopaminergic Drugs,Dopaminergic Effect,Dopaminergic Effects,Agents, Dopamine,Agents, Dopaminergic,Drugs, Dopamine,Drugs, Dopaminergic,Effect, Dopamine,Effect, Dopaminergic,Effects, Dopamine,Effects, Dopaminergic
D015647 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine A selective D1 dopamine receptor agonist used primarily as a research tool. 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-,R-SK&F 38393,SK&F-38393,SKF 38393-A,SKF-38393,SKF38393,RSK&F 38393,SK&F 38393,SK&F38393,SKF 38393,SKF 38393 A,SKF 38393A

Related Publications

A Sidhu, and R A Felder, and P A Jose, and P H Fishman
December 1988, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
A Sidhu, and R A Felder, and P A Jose, and P H Fishman
January 1987, Clinical and experimental hypertension. Part A, Theory and practice,
A Sidhu, and R A Felder, and P A Jose, and P H Fishman
August 1992, American heart journal,
A Sidhu, and R A Felder, and P A Jose, and P H Fishman
January 1973, Agressologie: revue internationale de physio-biologie et de pharmacologie appliquees aux effets de l'agression,
A Sidhu, and R A Felder, and P A Jose, and P H Fishman
August 2002, Acta physiologica Scandinavica,
A Sidhu, and R A Felder, and P A Jose, and P H Fishman
January 1988, Advances in experimental medicine and biology,
A Sidhu, and R A Felder, and P A Jose, and P H Fishman
October 1998, Naunyn-Schmiedeberg's archives of pharmacology,
A Sidhu, and R A Felder, and P A Jose, and P H Fishman
March 1977, British journal of pharmacology,
A Sidhu, and R A Felder, and P A Jose, and P H Fishman
July 2010, American journal of physiology. Renal physiology,
A Sidhu, and R A Felder, and P A Jose, and P H Fishman
March 1988, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!